(0.26%) 5 145.00 points
(0.17%) 38 507 points
(0.39%) 17 916 points
(-0.69%) $83.27
(0.83%) $1.939
(-0.02%) $2 346.80
(0.28%) $27.61
(2.55%) $945.65
(-0.23%) $0.933
(-0.27%) $11.00
(-0.38%) $0.797
(1.29%) $93.06
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 8.98%
@ $42.61
发出时间: 15 Feb 2024 @ 03:47
回报率: 5.70%
上一信号: Feb 14 - 04:34
上一信号:
回报率: 1.44 %
Live Chart Being Loaded With Signals
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1...
Stats | |
---|---|
今日成交量 | 822 968 |
平均成交量 | 607 741 |
市值 | 2.61B |
EPS | $0 ( 2024-02-27 ) |
下一个收益日期 | ( $-0.830 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -15.01 |
ATR14 | $0.0540 (0.12%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-19 | Shuman Harry | Sell | 115 | Common Shares |
2023-12-15 | Silverman Peter B. | Buy | 1 286 | Common Shares |
2023-12-15 | Silverman Peter B. | Buy | 21 100 | Common Shares |
2023-12-15 | Silverman Peter B. | Sell | 21 100 | Share Option (right to buy) |
2023-12-15 | Silverman Peter B. | Sell | 22 386 | Common Shares |
INSIDER POWER |
---|
69.28 |
Last 99 transactions |
Buy: 2 523 001 | Sell: 3 636 553 |
音量 相关性
Merus NV 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Merus NV 相关性 - 货币/商品
Merus NV 财务报表
Annual | 2023 |
营收: | $43.95M |
毛利润: | $-83.46M (-189.91 %) |
EPS: | $-3.00 |
FY | 2023 |
营收: | $43.95M |
毛利润: | $-83.46M (-189.91 %) |
EPS: | $-3.00 |
FY | 2022 |
营收: | $41.59M |
毛利润: | $29.60M (71.19 %) |
EPS: | $-2.92 |
FY | 2021 |
营收: | $49.11M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.730 |
Financial Reports:
No articles found.
Merus NV
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。